NCT04895709 2026-02-25
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute